- Conditions
- Alzheimer Disease
- Interventions
- Atorvastatin calcium
- Drug
- Lead sponsor
- Institute for the Study of Aging (ISOA)
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- Sun City, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 58
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
- Interventions
- Atorvastatin, Niacin, Colesevelam, Placebo Niacin, Placebo Colesevelam
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2019
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boise, Idaho • Seattle, Washington + 1 more
- Conditions
- Dyslipidemias, Cardiovascular Diseases, HIV Infections, Atherosclerosis
- Interventions
- Bempedoic acid, Placebo
- Drug · Other
- Lead sponsor
- Priscilla Hsue, MD
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 3
- States / cities
- Los Angeles, California • San Francisco, California • Houston, Texas
- Conditions
- Pre-diabetes
- Interventions
- Rosiglitazone, Placebo Rosiglitazone, Simvastatin
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetes, Dyslipidemia
- Interventions
- Academic detailing
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hypercholesterolemia
- Interventions
- Lapaquistat acetate and current lipid-lowering treatment, Current lipid-lowering treatment
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Columbus, Ohio
- Conditions
- Type 2 Diabetes
- Interventions
- Statin, PCSK9 inhibitor, Ezetimibe 10mg
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Placebo to Evolocumab, Ezetimibe, Placebo to Ezetimibe
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 20
- States / cities
- Carmichael, California • Los Angeles, California • Mission Viejo, California + 15 more
- Conditions
- Cholesterol Absorption
- Interventions
- clinoptilolite
- Dietary Supplement
- Lead sponsor
- Canadian Collaborative Research Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Cumming, Georgia
- Conditions
- Familial Hypercholesterolemia
- Interventions
- Evolocumab
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- lerodalcibep, evolocumab
- Drug
- Lead sponsor
- LIB Therapeutics LLC
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Evanston, Illinois • Cincinnati, Ohio
- Conditions
- Hypercholesterolemia, Medication Adherence
- Interventions
- Medication adherence intervention, Attention-control
- Behavioral
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Inclisiran
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 20 more
- Conditions
- Prostate Cancer
- Interventions
- ezetimibe 10mg-simvastatin 40mg
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hyperlipidemia
- Interventions
- XueZhiKang (XZK), a botanic product with multiple components, Placebo
- Drug
- Lead sponsor
- Beijing Peking University WBL Biotech Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Hollywood, Florida • Kansas City, Kansas + 5 more
- Conditions
- Dyslipidemia
- Interventions
- Evolocumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 5,035 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 144
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 136 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Inclisiran
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 43
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Greenwich, Connecticut + 32 more
- Conditions
- Dyslipidemia
- Interventions
- Evolocumab, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 27,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 326
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 275 more
- Conditions
- Familial Hypercholesterolemia - Heterozygous
- Interventions
- lerodalcibep 300 mg Monthly SC
- Biological
- Lead sponsor
- LIB Therapeutics LLC
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Hypercholesterolemia
- Interventions
- Secura then Futura, Futura then Secura
- Device
- Lead sponsor
- B. Braun Medical Inc.
- Industry
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Hartford, Connecticut • Kansas City, Kansas
- Conditions
- Familial Hypercholesterolemia
- Interventions
- Evolocumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- The Bronx, New York • Cincinnati, Ohio • Nashville, Tennessee
- Conditions
- Type 1 Diabetes
- Interventions
- Evolocumab Cartridge, Atorvastatin Calcium Tablets, Ezetimibe Tablets, 18F-FDG, Angiocatheter 20IV, J-Wire, GlycoCheck Glycocalyx Measurement Software
- Drug · Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- New York, New York
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2,067 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more
- Conditions
- Dyslipidemia
- Interventions
- Motivational Interviewing (MINT), Usual Care
- Behavioral · Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 779 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Miami, Florida